{"filing":{"accession_number":"0001628280-26-066601","cik":"0000001800","ticker":"ABT","company_name":"ABBOTT LABORATORIES","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"abt-20261021.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026066601/abt-20261021.htm"},"events":[{"id":36598,"run_id":33745,"accession_number":"0001628280-26-066601","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Abbott announced third-quarter 2026 financial results on October 21, 2026, disclosing net sales of $13.013 billion (14.5% reported growth, 7.0% comparable growth), GAAP diluted EPS of $0.53, and adjusted diluted EPS of $1.42. The news release, furnished as Exhibit 99.1, presents comprehensive quarterly results across all business segments (Nutrition, Diagnostics, Established Pharmaceuticals, Medical Devices) and reaffirms full-year 2026 adjusted EPS guidance. This is a standard quarterly earnings disclosure material to investors.","company_name":"ABBOTT LABORATORIES","ticker":"ABT","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41062,"accession_number":"0001628280-26-066601","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Abbott announced third-quarter 2026 financial results on October 21, 2026, disclosing net sales of $13.013 billion (14.5% reported growth, 7.0% comparable growth), GAAP diluted EPS of $0.53, and adjusted diluted EPS of $1.42. The news release, furnished as Exhibit 99.1, presents comprehensive quarterly results across all business segments (Nutrition, Diagnostics, Established Pharmaceuticals, Medical Devices) and reaffirms full-year 2026 adjusted EPS guidance. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T11:37:37.905069+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41062,"accession_number":"0001628280-26-066601","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Abbott announced third-quarter 2026 financial results on October 21, 2026, disclosing net sales of $13.013 billion (14.5% reported growth, 7.0% comparable growth), GAAP diluted EPS of $0.53, and adjusted diluted EPS of $1.42. The news release, furnished as Exhibit 99.1, presents comprehensive quarterly results across all business segments (Nutrition, Diagnostics, Established Pharmaceuticals, Medical Devices) and reaffirms full-year 2026 adjusted EPS guidance. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T11:37:37.905069+00:00","company_name":"ABBOTT LABORATORIES","ticker":"ABT","filing_date":"2026-10-21"}]}